Ketamine 2024 is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of ketamine and related compounds for affective disorders.
This highly anticipated event, due to take place in Oxford this year has been organised by Dr Rupert McShane, consultant Psychiatrist at Oxford Health NHS Foundation Trust and University of Oxford Department of Psychiatry, alongside his colleague Dr Sara Costi, Wellcome Trust Doctoral Fellow, and Univeristy of Oxford Department of Psychiatry,
Sessions will range widely. From discussion of practice-defining large RCTs to exciting preclinical mechanistic studies, from the operation of ketamine clinics in real-world settings to updates on the regulation of new devices and formulations to consideration of novel compounds – the full breadth of activity will be covered.
The programme for Ketamine 2024 is in development.
There is an outstanding list of international confirmed speakers so far including University of Oxford Rupert McShane and Lilian Weber, Harvard Medical Schools Amit Anand , Jansens Vice President, Disease Area Team Leader, Neuroscience Wayne Drevets, The National Institute of Drug Abuse Mike Michaelides and more.
Abstract submission is open until 12 February here.
This is an in person event with an option to attend virtually.